Risk of malignancies in patients treated with Sandimmun® for autoimmune diseases-Reference-Cited by-同舟云学术

Risk of malignancies in patients treated with Sandimmun® for autoimmune diseases

Published:1996 Issue: Volume: Page:141-148
ISSN:
Container-title:Cancer in Transplantation: Prevention and Treatment
language:
Short-container-title:

Author:

Lamarque V.,Monka C.,Commare M. C.,Krupp P.

Publisher

Springer Netherlands

Link

http://link.springer.com/content/pdf/10.1007/978-94-009-0175-9_17

Reference19 articles.

1. Gupta AK, Ellis CN, Goldfarb MT, et al. Cyclosporine A. Clin Dermatol 1989; 73: 98–110.

2. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101–3.

3. Cockburn ITR, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989; 2: 723–31.

4. Zwanenburg TSB, Suter W, Matter BE. Absence of genotoxic potential for Sandimmun® in experimental systems. Transplant Proc 1988; 20(suppl 3): 931–3.

5. Ryffel B. Experimental toxociological studies with cyclosporine A. In “Cyclosporine A”, Proc Internat Conference on Cyclosporin A, Cambridge (UK), September 1981. Publ. DJG White (Cambridge). Elsevier, Amsterdam, New York, Oxford; 1982: 45–75.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COLON CANCER FOR A PATIENT RECEIVING CYCLOSPORIN A FOR NEPHROTIC SYNDROME;Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association);2007

2. Long-Term ContinuousversusIntermittent Cyclosporin: Therapy for Psoriasis;The Journal of Dermatology;2003-04

3. Neoral® in the Treatment of Psoriasis: Consensus Treatment Guidelines;Journal of Cutaneous Medicine and Surgery;1997-04